

2020

Impact of cardiologist intervention on guideline-directed use of statin therapy

M. Cassagnol

O. Hai

S. A. Sherali

Northwell Health

K. D'Angelo

D. Bass

See next page for additional authors

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/publications>



Part of the [Cardiology Commons](#)

Recommended Citation

Cassagnol M, Hai O, Sherali SA, D'Angelo K, Bass D, Zeltser R, Makaryus AN. Impact of cardiologist intervention on guideline-directed use of statin therapy. . 2020 Jan 01; 12(8):Article 6987 [p.]. Available from: <https://academicworks.medicine.hofstra.edu/publications/6987>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors

M. Cassagnol, O. Hai, S. A. Sherali, K. D'Angelo, D. Bass, R. Zeltser, and A. N. Makaryus

Retrospective Cohort Study

Impact of cardiologist intervention on guideline-directed use of statin therapy

Manouchkathe Cassagnol, Ofek Hai, Shaqeel A Sherali, Kyla D'Angelo, David Bass, Roman Zeltser, Amgad N Makaryus

ORCID number: Manouchkathe Cassagnol 0000-0001-7809-202X; Ofek Hai 0000-0003-0972-2862; Shaqeel A Sherali 0000-0002-3666-797X; Kyla D'Angelo 0000-0002-1367-3349; David Bass 0000-0002-4067-6959; Roman Zeltser 0000-0001-9737-7266; Amgad N Makaryus 0000-0003-2104-7230.

Author contributions: Cassagnol M, Hai O, Zeltser R, Makaryus AN designed the research and wrote the paper; Sherali SA, D'Angelo K and Bass D performed the research, Zeltser R and Makaryus AN critically revised the manuscript for important intellectual content.

Institutional review board statement: NuHealth/Nassau University Medical Center Institutional Review Board; Approval IRB# 17-139.

Informed consent statement: This retrospective study with anonymized data does not require informed consent due to no identifiable data as approved by our institutional review board.

Conflict-of-interest statement: No conflicts of interest exist for any of the authors relating to this study.

Data sharing statement: No

Manouchkathe Cassagnol, Ofek Hai, Kyla D'Angelo, Roman Zeltser, Amgad N Makaryus, Department of Cardiology, NuHealth/Nassau University Medical Center, East Meadow, NY 11554, United States

Manouchkathe Cassagnol, Department of Clinical Health Professions, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11430, United States

Shaqeel A Sherali, Roman Zeltser, Amgad N Makaryus, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, United States

David Bass, St. Lawrence Health System, Potsdam, NY 13676, United States

Corresponding author: Amgad N Makaryus, MD, Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Chairman, Department of Cardiology, Nassau University Medical Center, 2201 Hempstead Turnpike, East Meadow, NY 11554, United States. amakaryu@numc.edu

Abstract

BACKGROUND

Statins have an important and well-established role in the prevention of atherosclerotic cardiovascular disease (ASCVD). However, several studies have reported widespread underuse of statins in various practice settings and populations. Review of relevant literature reveals opportunities for improvement in the implementation of guideline-directed statin therapy (GDST).

AIM

To examine the impact of cardiologist intervention on the use of GDST in the ambulatory setting.

METHODS

Patients with at least one encounter at the adult Internal Medicine Clinic (IMC) and/or Cardiology Clinic (CC), who had an available serum cholesterol test performed, were evaluated. The 2 comparison groups were defined as: (1) Patients only seen by IMC; and (2) Patients seen by both IMC and CC. Patients were excluded if variables needed for calculation of ASCVD risk scores were lacking, and if demographic information lacked guideline-directed treatment recommendations. Data were analyzed using student *t*-tests or χ^2 , as appropriate.

additional data.

STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Received: February 28, 2020

Peer-review started: February 28, 2020

First decision: April 25, 2020

Revised: May 13, 2020

Accepted: August 1, 2020

Article in press: August 1, 2020

Published online: August 26, 2020

P-Reviewer: Greenway SC

S-Editor: Wang JL

L-Editor: A

P-Editor: Wang LL



Analysis of Variance was used to compare rates of adherence to GDST.

RESULTS

A total of 268 patients met the inclusion criteria for this study; 211 in the IMC group and 57 in the IMC-CC group. Overall, 56% of patients were female, mean age 56 years (± 10.65 , SD), 22% Black or African American, 56% Hispanic/Latino, 14% had clinical ASCVD, 13% current smokers, 66% diabetic and 63% hypertensive. Statin use was observed in 55% ($n = 147/268$) of the entire patient cohort. In the IMC-CC group, 73.6% ($n = 42/57$) of patients were prescribed statin therapy compared to 50.7% ($n = 107/211$) of patients in the IMC group ($P = 0.002$). In terms of appropriate statin use based on guidelines, there was no statistical difference between groups [IMC-CC group 61.4% ($n = 35/57$) vs IMC group, 55.5% ($n = 117/211$), $P = 0.421$]. Patients in the IMC-CC group were older, had more cardiac risk factors and had higher proportions of non-white patients compared to the IMC group ($P < 0.02$, all).

CONCLUSION

Although overall use of GDST was suboptimal, there was no statistical difference in appropriate statin use based on guidelines between groups managed by general internists alone or co-managed with a cardiologist. These findings highlight the need to design and implement strategies to improve adherence rates to GDST across all specialties.

Key words: Statin use; Guideline directed statin therapy; Cardiologist; Ambulatory care; Adherence

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Statins have an important and well-established role in the prevention of atherosclerotic cardiovascular disease. However, several studies have reported widespread underuse of statins in various practice settings and populations. Review of relevant literature reveals opportunities for improvement in the implementation of guideline-directed statin therapy (GDST). We aimed to examine the impact of cardiologist intervention on adherence to GDST in the ambulatory setting. Our evaluation shows that although overall adherence to GDST was suboptimal, there was no statistical difference in appropriate statin use based on guidelines between groups managed by general internists alone or co-managed with a cardiologist. These findings highlight the need to design and implement strategies to improve adherence rates to GDST across all specialties.

Citation: Cassagnol M, Hai O, Sherali SA, D'Angelo K, Bass D, Zeltser R, Makaryus AN. Impact of cardiologist intervention on guideline-directed use of statin therapy. *World J Cardiol* 2020; 12(8): 419-426

URL: <https://www.wjgnet.com/1949-8462/full/v12/i8/419.htm>

DOI: <https://dx.doi.org/10.4330/wjc.v12.i8.419>

INTRODUCTION

Statins have an important and well-established role in the prevention of atherosclerotic cardiovascular disease (ASCVD). Large-scale clinical trials have shown that statins substantially reduce cardiovascular morbidity and mortality in both primary and secondary prevention. The American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults emphasizes identifying and treating individuals at the highest risk for developing ASCVD with statins^[1,2]. However, despite mounting evidence supporting its use, several studies have reported widespread underuse of statins in the ambulatory setting^[3], in secondary prevention^[4], and more frequently among women^[5], older adults, Blacks, Hispanics/Latinos, and those who are under/uninsured^[6]. Early skepticism of the feasibility of implementing the ACC/AHA guidelines in a patient population has been documented. One report found 56% predicted prescriber adherence to those guidelines in a retrospective simulated

analysis of a large academic medical practice^[6]. In a more recent study, one-third of patients with ASCVD and almost one-half of patients without ASCVD were not receiving guideline recommended moderate- to high-intensity statin therapy in cardiology practices after the publication of the 2013 ACC/AHA guideline^[1]. The most recent cholesterol 2018 guidelines from ACC/AHA continue to emphasize the use of statins as a primary treatment modality for eligible patients to achieve appropriate low-density lipoprotein cholesterol (LDL-C) reduction^[2].

Limited information is available regarding the appropriate implementation of the cholesterol guidelines as they pertain to evidence-based statin use. The objective of our study was to examine physician adherence to GDST in the ambulatory setting across multiple subgroups of patients and determine the impact of cardiologist intervention on GDST.

MATERIALS AND METHODS

Design and sample

A retrospective chart review was conducted of patients who had at least one encounter at the adult Internal Medicine Clinic (IMC) and/or Cardiology Clinic (CC) at our community tertiary care teaching hospital from May 2016 to April 2017 and who had an available serum cholesterol test performed. Patients were excluded if the following biometric variables needed for calculation of ASCVD risk score were unavailable: age, sex, race, systolic blood pressure (SBP), total cholesterol (TC), LDL-C, high density lipoprotein cholesterol (HDL-C), history of diabetes mellitus (DM), smoking status, and hypertension treatment status. In addition, patients whose demographics lacked guideline directed treatment recommendations were excluded (*e.g.*, age < 40 or > 79 years). The 2 comparison groups were defined as: (1) Patients only seen by IMC; and (2) Patients seen by both IMC and CC.

Definitions

The presence of clinical ASCVD included history of acute coronary syndrome, history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease. Moderate- and high-intensity statin was defined by statin dose that would lower LDL-C on average by 30%-49% and $\geq 50\%$ with daily dosing, respectively. Statin therapy utilized was categorized as appropriate or not appropriate GDST. As such, the presence of clinical ASCVD or LDL-C greater than 190 mg/dL, would indicate use of high-intensity statin (atorvastatin 40–80 mg or equivalent)^[1]. For primary prevention, the presence of a diagnosis of DM and/or ASCVD risk score > 7.5% would indicate the use of at least a moderate-intensity statin (atorvastatin 10-20 mg or equivalent) depending on patient tolerance^[1].

Data collection and assessment

Data collected included date of visit, date of lipid panel referenced, gender, age, body mass index, race/ethnicity, TC, HDL-C, SBP, hypertension and its treatment status, presence of clinically diagnosed DM, smoking status, history of ASCVD, clinically diagnosed hyperlipidemia and current statin use including type and dose/intensity. Data were entered into the ASCVD risk calculator, with 10-Year and lifetime ASCVD risk recorded. Treatment assigned by the physician at the last clinic visit was then compared to guideline recommended treatment, and labeled as appropriate or inappropriate. If a patient's LDL-C was greater than 190 mg/dL or if they had clinical ASCVD, then they would be eligible for high-intensity statin and use of the ASCVD risk calculator was not indicated and therefore not calculated, as per guideline recommendations.

Statistical analysis

Descriptive statistics are presented as mean \pm SD or number and percent. Baseline characteristics of subgroups were compared using student *t*-tests or χ^2 tests, as appropriate. χ^2 test analysis was used to analyze statistical significance between groups. Analysis of variance was used to test the statistical difference between means of continuous variables. Statistical significance was defined as $P < 0.05$. All statistical analyses were performed using SPSS version 26.0 (SPSSTM Inc., Chicago, IL, United States).

RESULTS

A total of 268 patients met the inclusion criteria for this study. **Table 1** describes the demographic characteristics of the study population, 56% were female, mean age was 56 years (± 10.65 , SD), 22% identified as Black or African American and 56% identified as Hispanic/Latino. Approximately 14% of the cohort had clinical ASCVD as previously defined, 13% were current smokers, 66% were diabetic, and 63% were hypertensive. Statin use was observed in 55% of the entire cohort, with moderate-intensity statins being the most commonly prescribed.

Of the total 268 patients, 211 and 57 patients were in the IMC only and IMC-CC group, respectively (**Table 2**). Overall, in the IMC-CC group, 73.6% ($n = 42/57$) of patients were prescribed statin therapy compared to 50.7% ($n = 107/211$) of patients in the IMC group ($P = 0.002$). In terms of appropriate statin use based on guidelines, there was no statistical difference between groups [IMC-CC group 61.4% ($n = 35/57$) *vs* IMC group, 55.5% ($n = 117/211$), $P = 0.421$]. Patients in the IMC-CC group had significantly higher cardiac risk as compared to the IMC group: Clinical ASCVD history (35.1% *vs* 18%, $P < 0.001$), diabetes (47.3% *vs* 30.3%, $P = 0.016$), hypertension (80.7% *vs* 59.2%, $P = 0.003$) and smoking history (47.4% *vs* 26.1%, $P = 0.002$). Patients in the IMC-CC group were significantly older (mean age 62.1 years *vs* 55.5 years, $P < 0.001$) and had a higher proportion of non-white patients (49.6% *vs* 29.4%, $P = 0.021$) compared to the IMC group. Mean LDL-C and TC levels were lower in the IMC-CC group *vs* the IMC group (mean LDL-C, 110.36 mg/dL *vs* 123.98 mg/dL, $P = 0.013$) and (TC, 187.67 mg/dL *vs* 204.13, $P = 0.018$).

DISCUSSION

In our evaluation of real-world cholesterol management, we found that adherence to GDST by physicians occurred in about half the patients eligible for statin therapy. The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults (which were the latest available guidelines during our study period) recommends statins as first-line lipid lowering therapy for both primary and secondary prevention^[7]. Furthermore, data from the National Health and Nutrition Examination Surveys estimated an increase in statin-eligible patients by 2.4 million, 2.2 million, and 8.2 million in patients with ASCVD, diabetes, and in primary prevention, respectively^[8]. Given recent shifts in the cholesterol treatment paradigm from the older ATP III guidelines^[9], Schoen *et al*^[6] predicted 56% adherence with the 2013 blood cholesterol guidelines in a retrospective analysis. In another study, Pokharel *et al*^[7] evaluated trends in the use of statin therapy and non-statin therapy in cardiology practices, before and after the publication of the 2013 ACC/AHA guidelines. They found modest, yet significant increases in the use of moderate- to high-intensity statins in ASCVD patients and no change in the other statin benefit groups and nearly half of statin eligible patients did not receive a statin^[7]. By comparison, our real-world study demonstrated similar trends in that nearly half of statin eligible patients did not receive a statin. Furthermore, adherence to GDST by general internists tended to be lower (55.5%) when compared to patients who were also being managed by a cardiologist (61.4%), although this difference was not statistically significant. Hence, being evaluated by a cardiology specialist did not appear to have any additional impact on the use of GDST at our institution.

The literature also notes that different factors and patient characteristics affect implementation and use of GDST. Schoen *et al*^[10] found that women and patients with diabetes were less likely to be treated optimally; and this in turn, could impact cardiovascular outcomes. In our study, there was a higher proportion of patients with clinical ASCVD and diabetes that were seen by the cardiologist. These patients also had lipid profiles that necessitated therapy. This may suggest that at our institution, higher risk patients needing further LDL-C reduction are appropriately being managed by cardiology specialists who are trained to address these complex situations. Furthermore, patients who were managed by the cardiologist achieved significantly lower LDL-C levels, which may translate to greater reduction in future coronary heart disease events^[11]. Further long-term studies of these patients may shed light on such outcomes.

Several other studies have reported similar trends in 2013 ACC/AHA guideline implementation, however, very little is known about the barriers to adherence. Clough *et al*^[12] found that although community-based physicians often accurately estimated risk, beliefs and approach to statin discussion varied and these variables had minimal

Table 1 Patient Clinic demographics, *n* = 268, *n* (%)

Patient characteristics	Data
Age (yr), mean	56 (\pm 10.65, SD)
Sex	
Male	118 (44)
Female	150 (56)
Race	
White	180 (67.2)
Black	60 (22.2)
Other	28 (10.4)
Ethnicity	
Hispanic/Latin-o,-a	151 (56.3)
Smoker	
Never	184 (68.7)
Former	48 (17.9)
Current	34 (12.7)
Unknown	2 (0.7)
ASCVD	38 (14.2)
mean ASCVD score	12.1%
Diabetes	177 (66)
Hypertension	171 (63.8)
Statin prescribed	149 (55)
Low	11 (4.1)
Moderate	82 (30.6)
High	56 (20.9)
Clinical laboratory profile	
TC (mg/dL), mean	200.63 (46.7, SD)
LDL-C (mg/dL), mean	121.08 (36.9, SD)
HDL-C (mg/dL), mean	51.17 (15.2, SD)
SBP (mmHg), mean	132 (19.2, SD)

TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; SBP: Systolic blood pressure.

impact on low rates of statin prescribing. An inter-professional approach using the patient-centered medical home model made no difference in guideline implementation within a primary care practice^[12]. It has been well established that it may take up to 17 years for evidence to be fully implemented into practice, which may explain the low statin use in the overall study cohort^[13]. More studies will need to be conducted to fully understand these barriers. However, a recent study has shown that since the publication of the 2013 ACC/AHA guidelines (and subsequent 2018 guidelines), cholesterol levels and statin use have improved in the US^[14]. Future studies should be conducted to evaluate the long-term impact of the latest cholesterol guidelines on adherence to GDST^[15].

Our study has several limitations including the short period of analysis, its retrospective design, and small sample size. As noted, studies have demonstrated that it may take up to 17 years for evidence to be fully implemented into practice^[13], and therefore the period of analysis for our study [which occurred within 3 years (2016 to 2017) following guideline publication], may simply reflect the lag time between guideline publication and implementation. Furthermore, our study relied on the

Table 2 Adherence to guideline-directed statin therapy and patient characteristics by group, n (%)

All patients (n = 268)	IMC only (n = 211)	IMC/CC (n = 57)	P value
Statin prescribed	107 (50.7)	42 (73)	0.002
Appropriate intensity statin prescribed	117 (55.5)	35 (61.4)	0.421
Distribution of population			
Age(years), mean	55.47 (± 10.11, SD)	62.14 (± 11.08, SD)	< 0.001
ASCVD	18(8.5)	20 (35.1)	< 0.001
DM	64 (30.3)	27 (47.3)	0.016
Hypertension	125(59.2)	46 (80.70)	0.003
Smoking history (current and former)	55 (26.1)	27 (47.4)	0.002
Non-white	62 (29.4)	26 (45.6)	0.021
Hispanic, Latino	127 (60.2)	24 (42.1)	0.015
LDL-C (mg/dL), mean	123.98 (± 34.77, SD)	110.36 (± 42.47, SD)	0.013
TC (mg/dL), mean	204.13 (± 44.96, SD)	187.67 (± 50.77, SD)	0.018
HDL-C (mg/dL), mean	50.4 (± 14.1, SD)	53.9 (± 18.6, SD)	0.126

IMC: Internal Medicine Clinic; CC: Cardiology Clinic; TC: Total cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High density lipoprotein cholesterol; SBP: Systolic blood pressure.

accuracy and completeness of physician documentation which may have impacted the determination of physician adherence to guideline recommendations. Our analysis does not account for other reasons why GDST was not implemented (*e.g.*, patient factors, physician attitudes towards prescribing, adverse reactions, and cost of therapy). Additionally, our study did not account for patient adherence to prescriber recommendations. Regardless of statin treatment, we obtained information from the lipid panel which may not have impacted high-risk cohorts but underestimated statin eligibility for other cohorts (*e.g.*, patient previously prescribed statin, but at the time of assessment patient may not have appeared to be eligible for statin therapy based on cholesterol results).

In conclusion, our study compared the use of GDST in patients managed by general internists and those co-managed by a cardiologist. As expected, patients with higher cardiac risk factors and co-morbidities were more likely to be co-managed by a cardiologist and placed on statin therapy. In terms of appropriate statin use based on guidelines, there was no statistical difference in proportion of patients receiving GDST between groups managed by general internists alone or co-managed with a cardiologist; however, there was a significantly greater use of statins in patients co-managed by a cardiologist. Overall, statin use in this population is comparable to what other studies have shown and highlights the need to design and implement strategies to improve prescriber adherence to GDST.

ARTICLE HIGHLIGHTS

Research background

Statins have an important and well-established role in the prevention of atherosclerotic cardiovascular disease (ASCVD). However, several studies have reported widespread underuse of statins in various practice settings and populations.

Research motivation

Review of relevant literature reveals opportunities for improvement in the implementation of guideline-directed statin therapy (GDST).

Research objectives

In this study, we aimed to examine the impact of cardiologist intervention on the use of statin therapy in the ambulatory setting.

Research methods

We conducted a retrospective chart review of patients who had at least one encounter at the adult Internal Medicine Clinic (IMC) and/or Cardiology Clinic (CC) and who had an available serum cholesterol test performed. The 2 comparison groups were defined as: (1) Patients only seen by IMC; and (2) Patients seen by both IMC and CC. Baseline characteristics of subgroups were compared.

Research result

A total of 268 patients met the inclusion criteria for this study. Approximately, 14% had clinical ASCVD, 13% were current smokers, 66% were diabetic, and 63% were hypertensive. Statin use was observed in 55% of the entire cohort, with moderate-intensity statins being the most commonly prescribed. Overall, in the IMC-CC group, 73.6% of patients were prescribed statin therapy compared to 50.7% of patients in the IMC group. There was no statistical difference in the use of GDST between groups.

Research conclusions

Our study compared the use of GDST in patients managed by general internists and those co-managed by a cardiologist. Overall, statin use in this population is comparable to what other studies have shown and highlights the need to design and implement strategies to improve prescriber adherence to GDST.

REFERENCES

- 1 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; **63**: 2889-2934 [PMID: 24239923 DOI: 10.1016/j.jacc.2013.11.002]
- 2 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; **139**: e1082-e1143 [PMID: 30586774 DOI: 10.1161/CIR.0000000000000625]
- 3 Persell SD, Brown T, Lee JY, Shah S, Henley E, Long T, Luther S, Lloyd-Jones DM, Jean-Jacques M, Kandula NR, Sanchez T, Baker DW. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial. *Circ Cardiovasc Qual Outcomes* 2015; **8**: 560-566 [PMID: 26555123 DOI: 10.1161/CIRCOUTCOMES.115.001723]
- 4 Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, Ting HH, Chan PS. Statin use in outpatients with obstructive coronary artery disease. *Circulation* 2011; **124**: 2405-2410 [PMID: 22064595 DOI: 10.1161/CIRCULATIONAHA.111.038265]
- 5 Gopal DM, Santhanakrishnan R, Wang YC, Ayalon N, Donohue C, Rahban Y, Perez AJ, Downing J, Liang CS, Gokce N, Colucci WS, Ho JE. Impaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome. *J Am Heart Assoc* 2015; **4**: e001597 [PMID: 25758604 DOI: 10.1161/JAHA.114.001597]
- 6 Schoen MW, Salas J, Scherrer JF, Buckhold FR. Cholesterol treatment and changes in guidelines in an academic medical practice. *Am J Med* 2015; **128**: 403-409 [PMID: 25460526 DOI: 10.1016/j.amjmed.2014.10.039]
- 7 Pokharel Y, Tang F, Jones PG, Nambi V, Bittner VA, Hira RS, Nasir K, Chan PS, Maddox TM, Oetgen WJ, Heidenreich PA, Borden WB, Spertus JA, Petersen LA, Ballantyne CM, Virani SS. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. *JAMA Cardiol* 2017; **2**: 361-369 [PMID: 28249067 DOI: 10.1001/jamacardio.2016.5922]
- 8 Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. *N Engl J Med* 2014; **370**: 1422-1431 [PMID: 24645848 DOI: 10.1056/NEJMoal315665]
- 9 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; **106**: 3143-3421 [PMID: 12485966 DOI: 10.1161/circ.106.25.3143]
- 10 Schoen MW, Tabak RG, Salas J, Scherrer JF, Buckhold FR. Comparison of Adherence to Guideline-Based Cholesterol Treatment Goals in Men Versus Women. *Am J Cardiol* 2016; **117**: 48-53 [PMID: 26589821 DOI: 10.1016/j.amjcard.2015.10.007]
- 11 Gotto AM Jr, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial Data Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. *Circulation* 1999; **99**: E1-E7 [PMID: 10051310 DOI: 10.1161/01.CIR.99.1.E1]

- 10.1161/01.cir.99.8.e1]
- 12 **Clough JD**, Martin SS, Navar AM, Lin L, Hardy NC, Rogers U, Curtis LH. Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription. *J Am Heart Assoc* 2019; **8**: e010241 [PMID: 30681391 DOI: 10.1161/JAHA.118.010241]
 - 13 **Hinds A**, Lopez D, Rascati K, Jokerst J, Srinivasa M. Adherence to the 2013 Blood Cholesterol Guidelines in Patients With Diabetes at a PCMH: Comparison of Physician Only and Combination Physician/Pharmacist Visits. *Diabetes Educ* 2016; **42**: 228-233 [PMID: 26902526 DOI: 10.1177/0145721716631431]
 - 14 **Institute of Medicine (US) Committee on Quality of Health Care in America**. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, US: National Academies Press, 2001 [PMID: 25057539 DOI: 10.17226/10027]
 - 15 **Patel N**, Bhargava A, Kalra R, Parcha V, Arora G, Muntner P, Arora P. Trends in Lipid, Lipoproteins, and Statin Use Among U.S. Adults: Impact of 2013 Cholesterol Guidelines. *J Am Coll Cardiol* 2019; **74**: 2525-2528 [PMID: 31727291 DOI: 10.1016/j.jacc.2019.09.026]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

